cyrilzakka/clinical-trials huggingface dataset:
Disability Level and Trunk Control in Individuals With Multiple Sclerosis

Trunk control disorders are frequently encountered in individuals with MS. Trunk control is very important for safe and quality movement. Impairment of trunk control reduces the level of independence of individuals during activities of daily living. For this reason, it is extremely important to evaluate the trunk in the examination and treatment of individuals. When the literature was examined, it was seen that studies examining trunk control were insufficient. Therefore, our study was planned to investigate the relationship between disability level and trunk control in individuals with MS.


Eligibility Criteria:
Inclusion Criteria:

* Being between the ages of 18-65
* Having a definite diagnosis of MS
* Expanded Disability Status Scale (EDSS) score of 8.5 and below
* Not having an attack in the last 3 months

Exclusion Criteria:

* Having another musculoskeletal, cardiovascular, pulmonary, metabolic, or neurological disease severe enough to preclude participation in the study.
* Having severe vision and hearing problems
* The presence of severe cognitive impairment detected by the physician at a level that prevents the tests from being performed.
Eradication Rates of Helicobacter Pylori and Its Affecting Factors

The purpose of this study is to investigate the trend of eradication rates of first-line triple therapy for Helicobacter pylori in recent ten years and clinical factors that affect the eradication in Korean.

A PPI triple regimen combining a proton pump inhibitor(PPI) with two antibiotics (amoxicillin and clarithromycin) is currently considered the gold standard therapy for eradication of H. pylori. However, recently the eradication rate with first-line treatment has a tendency to decrease because of increasing antibiotics resistance. In addition, PPI is mainly metabolized by cytochrome p450 2C19 (CYP2C19) in the liver and several reports have suggested that differences in th CYP2C19 genotype are associated with H. pylori eradication failure. Thus, the first aim of this study is to investigate the trend of eradication rates of first-line triple therapy in recent ten years. And the second aim is to analyze the antibiotics resistance rate for H. pylori by using culture minimal inhibitory concentrations(MICs) result and to analyze the association between CYP2C19 genotype and eradication rate of H.pylori. And also investigate the other clinical factors (age, gender, underlying disease, cigarette smoking and alcohol use) that affect the eradication rate.

Eligibility Criteria:
Inclusion Criteria:

* Patients who proven H. pylori infection by invasive or non-invasive H. pylori test
* Patients treated with First-line triple therapy (PPI + Amoxicillin + Clarithromycin)

Exclusion Criteria:

* Previous eradication therapy for H. pylori
* Follow-up loss patients after eradication therapy
* Other treatment regimen
* Poor medication compliance (\<80%)
EffectiveNess of a Multimodal preHAbilitation Program in patieNts With Bladder canCEr Undergoing Cystectomy

Currently, the potential value of a multimodal prehabilitation program in bladder cancer has not been extensively studied. The investigators designed the ENHANCE study to assess the effect of a structured multimodal prehabilitation program in 154 patients with bladder cancer on the number (primary endpoint) and severity of complications within 90 days, length of hospital stay, readmissions, physical fitness, muscle strength, physical functioning, nutritional status, smoking behaviour, anxiety and depression, fatigue, quality of life, physical activity, tumor tissue characteristics, and healthcare costs.

The ENHANCE study is a multicenter, randomized controlled trial. The intervention group will participate in a prehabilitation program of 4-6 weeks before surgery, and additionally during neoadjuvant chemotherapy if applicable. The prehabilitation program consist of a tailored exercise program, nutritional support and if relevant smoking cessation and/or psychological counselling. The exercise program is under supervision of an oncology specialized physiotherapist and comprises aerobic-, resistance- and breathing- and relaxation exercises. Patients will be asked to be physically active for an additional 2 times a week for at least 30 minutes. A dietician will provide nutritional support and give dietary advice to increase protein intake to enhance the anabolic effect on muscle mass. Additionally, patients will receive a supplement containing 30 g of high quality whey-protein daily preferably before sleep and after the supervised training. Patients who score high on anxiety and depression will be offered a referral to a psychological support. Intensive counselling and nicotine replacement therapy will be offered to all patients who smoke. Patients in the intervention group will be asked to keep a diary to track unsupervised activity and to track intake of the protein supplementation. The physical activity level in both groups will be obtained via questionnaire.

Eligibility Criteria:
Inclusion Criteria:

* Histologically confirmed, primary, bladder cancer (cTa-4N0/N+M0),
* Planned to undergo radical cystectomy,
* Age ≥ 18 years.

Exclusion Criteria:

* Subjects with severe cognitive or psychiatric disorders,
* Subjects who are operated within 3 weeks,
* Subjects with insufficient command of the Dutch language, which precludes them from following study instructions or completing study questionnaires,
* Subjects who have contraindications to safely perform exercise training or testing (i.e., CPET),
* Subject who are unable or unwilling to participate in the intervention.
Integrating Stroke Survivors Into Cardiac Rehabilitation

The intervention trial will examine the effectiveness and feasibility of integrating stroke survivors into an existing hospital-based cardiac rehabilitation program at Novant Health in Charlotte, NC. Stroke survivors will be recruited through hospital system providers and physical therapists (PTs) for entry into a multidisciplinary, three-month cardiac rehabilitation program. This program consists of three sessions per week of supervised cardiovascular endurance and strength training, stretching, relaxation and education. Participants will be stroke survivors, have completed formal physical and occupational rehabilitation (if applicable), and have treating provider approval.


Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis of stroke
* Completion of physical and occupational therapy (if applicable)
* Clearance by treating medical provider
* Ability to walk at least 40 meters independently (with or without assistive device)
* Ability to transfer sit to stand without assistance
* Ability to follow instructions and provide information on exertion, pain and distress

Exclusion Criteria:

* Acute medical problem rendering exercise unsafe
* Significant pain that prevents standing or interferes with movement
* History of additional, non-stroke, neurological condition
Improve Acute Reperfusion Treatment Quality for Stroke in China, IMPROVE: Stroke Care in China

In order to bridge the great gaps, Chinese Stroke Association (CSA) and American Heart Association (AHA) sought to develop, conduct, and assess a multifaceted quality improvement intervention to increase the adherent rate of IV tPA and ET and improve 3-month clinical outcomes for these patients through our cluster-randomized stepped-wedge IMPROVE: Stroke in China trial.


Eligibility Criteria:
Inclusion Criteria:

Hospitals：

1. Voluntary.
2. Hospitals from CSCA.
3. Secondary or tertiary public hospitals with an emergency department and neurologic wards that receive patients with AIS.
4. Have a 24\*7 on-call stroke team.
5. Have the capacity of IV rt-PA thrombolytic therapy or/and endovascular treatment.
6. Implement at least 10 patients' rt-PA or/and endovascular treatment during the last year.
7. Admit at least 5 patients of acute ischemic stroke within 24 hours after onset each month.
8. Have full desire to improve the procedure of treatment of acute ischemic stroke.
9. Have good cooperation among Neurology department, Emergency department, Interventional department, Neurosurgery department, Laboratory and Radiology department.

Patients： Patients who are ≥18 years old were eligible for inclusion if they presented with acute ischemic stroke diagnosed by CT and/or MRI and arrived at hospital within 6 hours after symptom onset.

Exclusion Criteria:

Hospitals：

1. Hospitals that can not comply with the protocol and finish the research.
2. Grade-one hospitals and non cerebral vascular disease specialized hospitals.
3. Hospitals involved in other stroke care quality improvement projects or relevant clinical trials.

Patients：

1）Patients refuse to participate in this study
A Study of NCS-01 in Patients With Acute Ischemic Stroke

This is an initial Phase1/2 dose-finding, randomized, multi-center study to evaluate the safety and tolerability of NCS-01 in patients with acute ischemic stroke. All patients will be randomized within 48 hours of stroke onset. This study will be conducted in 2 stages.


Eligibility Criteria:
Inclusion Criteria:

* Males and females, age 18 to 85 years inclusive
* Clinical evidence of acute ischemic unilateral cerebral infarction
* - Evidence of neurologic deficits as defined by NIHSS 6 to 18 or NIHSS \< 6 with Fugl-Meyer upper extremity subtotal 6 to 40 inclusive
* Women of child bearing potential who agrees to take acceptable birth control as described in the ICF
* Provide written informed consent before participation, either by patient or a legal representative

Exclusion Criteria:

* Progressive neurologic deficit
* An inability to undergo an MRI scan
* Any malignancies within the last 5 years
* Previous organ transplantation
* Participation in another clinical trial with an investigational drug, device or biologic within the preceding 3 months
* Women of childbearing potential with a positive pregnancy test
* Already dependent in activities of daily living (Rankin scale 3 or more) before the present acute stroke
* Known hypersensitivity, allergy or intolerance to the similar biologic interventions
* Any other clinically relevant acute or chronic diseases which could interfere with patients' safety during the trial, or expose them to undue risk, or which could interfere with study objectives judged by Investigator based on medical history, physical examination, laboratory tests and/or ECG
The Efficacy and Safety of Pulsed Radiofrequency Combined With Continuous Radiofrequency for the Trigeminal Neuralgia

Trigeminal neuralgia is a very painful condition, and radiofrequency therapy is reserved for patients who are resistant or intolerant to pharmacological therapy. Continuous radiofrequency and pulsed radiofrequency both have advantages and disadvantages. Recently, studies have found that pulsed radiofrequency combined with low-temperature (\<65 °C) continuous radiofrequency increases the efficacy of the treatment, without leading to a significant increase in complications caused by nerve lesions. However, these reports have some limitations. The investigators plan to conduct a randomized, controlled study to compare the efficacy of applying high-voltage pulsed radiofrequency, with and without low-temperature continuous radiofrequency, to the gasserian ganglion for the treatment of trigeminal neuralgia. The primary outcome will be the effectiveness of the treatment after 12 months which is the percentage of participants with a modified Barrow Neurological Institute Pain Intensity Score between I-III.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosed with trigeminal neuralgia according to the International Classification of Headache Disorders, 3rd Edition criteria.
* Aged 18-75 years (inclusive), no sex limitation.
* Suffering from severe trigeminal neuralgia that cannot be alleviated effectively using conservative medical therapy such as carbamazepine, oxcarbazepine.
* Numeric rating scale score≥7 before the procedure.
* Agreed to sign the informed consent form.

Exclusion Criteria:

* Secondary trigeminal neuralgia such as trigeminal neuralgia attributed to a space-occupying lesion or multiple sclerosis.
* Infection at the puncture site.
* A history of psychiatric disease.
* Disorder indicated in the results of routine blood tests, hepatic function, renal function, coagulation function, electrocardiogram, or chest X-ray.
* Serious systemic diseases such as uncontrolled hypertension or diabetes, and cardiac dysfunction (II-III of the New York Heart Association classification).
* A history of abuse of narcotics.
* A history of receiving continuous radiofrequency to the gasserian ganglion or peripheral branches; glycerol rhizolysis; balloon compression; gamma knife; or any other neuroablative treatments.
* A history of receiving microvascular decompression.
Infective Endocarditis Surgery Using Conventional Prosthetic Valves Versus Cryopreserved Aortic Homograft

: Evidence suggested that autologous or allogeneic tissue is more suitable to synthetic material in an infected field. Given the unwillingness of some surgeons to use artificial foreign materials, such as conventional mechanical or stent xenograft valve prostheses, cryopreserved aortic homografts (CAH) have been recommended revealing favorable outcomes in aortic valve endocarditis (AVE) surgery (1-5). This aspect is even more evident in cases involving prosthetic valve endocarditis (PVE) and other complex and aggressive lesions involving the aortic root and intervalvular fibrosa with abscess formation. However, most of these reports are fixed on single-arm observational studies without comparing CAH with conventional prostheses.

The key question of this study is to establish the difference in treatment failure (death, recurrent aortic valve regurgitation and reoperation), all-cause and cause-specific (cardiac vs noncardiac) mortality, hospitalizations for heart failure during follow-up (structural/non structural valve deterioration, thromboembolism and recurrent endocarditis) in patients who received the CAH vs conventional mechanical or stent xenograft valve prostheses for aortic valve replacement (AVR) secondary to infective endocarditis (IE)

The target population enrolled in the study includes patients with aortic-valve endocarditis at risk of embolization, heart failure and uncontrolled infection undergoing AVR with the use of CAH or conventional mechanical or stent xenograft valve prostheses. Individuals were adequately treated per applicable standards, including for the treatment of infection, LV dysfunction and heart failure. Patients enrolled in the studies were NYHA functional class II, III, or outpatient NYHA IV.

Three groups of patients are included in the study. Patients who were managed with CAH, patients who received AVR with conventional stented xenograft and recipients of AVR undergoing surgery with the use of mechanical prostheses.

Eligibility Criteria:
Inclusion Criteria:

* Duke Criteria
* Uncontrolled Infection Local abscess Large vegetation False aneurysm, Fistula, Dehiscence of PV
* Embolism Large vegetation \>10mm, persistent infection
* Heart Failure Involvement of aortic root, intervalvular fibrosa, pulmonary edema, cardiogenic shock

Exclusion Criteria :

* Pediatric
* Any echocardiographic evidence of absence of IE
Serotonin and the Upper Airway in Obstructive Sleep Apnea

The purpose of this study is to determine if a certain medication, alone or combined with another medication, will increase muscle activity in the upper airway in people who do and people who do not have sleep apnea. The medications being studied are paroxetine, a commonly used antidepressant, and 5 hydroxy-tryptophan (5HTP), which also can be used as a dietary supplement without a prescription. Because the effects of paroxetine in previous studies were not very large, we will also study it combined with 5HTP to see if the effect on the upper airway muscles is greater.


Eligibility Criteria:
Group A: 20 Adult patients with mild to severe sleep apnea. If patients are being treated with nasal CPAP, they will continue treatment except on study nights.

Group B: 20 normal adult non-snoring subjects.
Schedules of Dexamethasone in Patients Incorrectly Taking Dexamethasone Premedication (REaCT-dexamethasone)

Docetaxel chemotherapy is commonly used in patients with breast cancer. With the widespread use of steroid premedication, the incidence of fluid retention and skin toxicity side effects has been minimal. Premedication with dexamethasone (8mg twice daily) is recommended starting the day before chemotherapy and continuing for three days. Patients may forget to take all or part of their premedication prior to docetaxel administration, and additional doses of steroids are frequently give in place of the forgotten oral dose. The processes around treating patients who have incorrectly taken their medication are cumbersome leading to significant delays in patients receiving their chemotherapy while the chemotherapy nurse tries to contact the patients treating physician for guidance on the dose and route of dexamethasone they want administered. Most importantly with the current standard of care procedure, by the time the chemotherapy nurse, pharmacist and medical oncologist have spoken and made a treatment plan, the patient has been waiting for on average of an additional 1-2 hours before actually starting their chemotherapy.

This study will randomize cancer patients to a standard dose of dexamethasone 8mg orally or to contact the physician to see what dose they recommend. The current trial proposal could therefore reduce the time for which patients are waiting to receive their chemotherapy, improving time patients need to spend in the hospital and significantly improving practice not just in Ottawa but globally.

Eligibility Criteria:
Inclusion Criteria:

* Patients receiving docetaxel chemotherapy for cancer
* Have incorrectly taken some or all of their dexamethasone premedication
* ≥19 years of age

Exclusion Criteria:

* Contraindication to dexamethasone
* Unable to give informed consent
* Already included in the study during a prior cycle
The PAWS-COVID-19 (Pediatric AirWay complicationS COVID-19) Registry

The COVID-19 pandemic has disrupted anesthesia care all over the world. There remains very little data on current practice patterns and patient outcomes, particularly in anesthetized children. This is a prospective observational, multi-center study to investigate airway management related outcomes in children undergoing anesthesia during this pandemic. The investigators will compare the incidence of complications (particularly hypoxemia) in patients with COVID-19 to those who are COVID-19 negative during airway management.

PAWS COVID-19 Registry https://is.gd/PEDICOVID19

Registration link https://is.gd/researchrequest


Eligibility Criteria:
Inclusion Criteria:

* Undergoing an inpatient or outpatient procedure under general anesthesia with or without regional analgesia
* Undergoing a diagnostic procedure under sedation or general anesthesia
* Undergoing an urgent or emergent procedure performed during and outside of the regular operating room schedule hours.

Exclusion Criteria:

* Age \> 18 years.
* Children admitted to the operating room already intubated
* Children who require tracheal intubation for life-threatening conditions in the emergency department, intensive care, or hospital ward.
Childhood Trauma and Escape Decision Dynamics

The purpose of this study is to evaluate the effects of childhood maltreatment on cognitive and reactive fear.

Childhood maltreatment dramatically increases the risk for psychiatric disorders accompanied by profound difficulties in social interactions. However, it is still unclear how childhood maltreatment affects social interactions in adulthood. In this study, we examine how childhood maltreatment may modulate threat sensitivity assessed by the distance at which an individual flees from an approaching threat. While rapid escape decisions rely on "reactive fear" circuits, slower escape decisions are associated with "cognitive fear" circuits. Based on previous observations of altered early sensory processing, we expect that childhood maltreatment affects both cognitive and reactive fear circuits.

Eligibility Criteria:
Inclusion Criteria:

* Healthy subjects with varying levels of childhood maltreatment

Exclusion Criteria:

* current psychiatric illness
* current psychiatric medication or psychotherapy
* MRI contraindication (e.g. metal in body, claustrophobia)
* pregnancy
Effect of Invasive and Non Invasive Mechanical Ventilation on Feeding Delivery in COPD Elderly Patients

COPD patients requiring ventilation may benefit from invasive or non invasive ventilation. Non invasive ventilation is often incompatible with oral or enteral feding, due to gastric dilatation and full mask therapy. At the other hand, invasive ventilation is associated with incomplete enteral feeding and nutrition requirements are not reached. The aim of the study was to compare the feeding delivery of COPD patients receiving invasive or non invasive mechanical ventilation.


Eligibility Criteria:
Inclusion Criteria:

* COPD patients requiring mechanical ventilation (invasive and non invasive)
A Complicated Skin and Soft-tissue Infection Patient Registry

The purpose of this registry is to better understand (1) complicated skin and soft-tissue infections requiring hospitalization, and (2) clinical and economic outcomes in hospitalized patients receiving intravenous antibiotic therapy.

A prospective, multi-center, observational study involving 1200 patients hospitalized for the treatment of cSSTIs. The study will be conducted at approximately 50 hospitals in the US. Patients who consent to participate in the registry will be enrolled in the registry within 24 hours of initial IV antibiotic therapy for treatment of one or more cSSTI types. Sites will treat patients according to their usual clinical practice. The objective of this registry is to characterize cSSTIs with respect to patient characteristics and describe patient outcomes.

Eligibility Criteria:
Inclusion Criteria:

* Patients with a diagnosis of complicated skin and soft-tissue infection
* Patients who require IV antibiotic therapy as a primary treatment regimen
* Patients who are deemed to be cognitive and able to provide written informed consent and follow-up information.

Exclusion Criteria:

* Patients with a diagnosis at the index infection site of necrotizing soft tissue infection, burn, gangrene, decubitus ulcer, animal or human bites, known or suspected osteomyelitis, or mediastinitis
* Patients for whom amputation or a complete resection of the infection site is a planned component of treatment
* Patients who are pregnant
* Patients simultaneously participating in any interventional clinical trial
* Patients with any other known or suspected condition that may jeopardize adherence to registry protocol requirements
* Patients who are employees of the investigator or study hospital